Clostridium difficile

Clostridium difficile

Latest Posts

  • Cidrap EDU, Clostridium difficile, RSS
Study highlights optimal strategies for fecal transplantation in C diff patients​
  • Cidrap EDU, Clostridium difficile, RSS
Trial data show Rebyota is safe, effective in immune-compromised patients with recurrent C diff​
  • Cidrap EDU, Clostridium difficile, RSS
Study examines C diff recurrence, risk factors in cancer patients​
  • Cidrap EDU, Clostridium difficile, RSS
Study highlights demographic, socioeconomic disparities in C difficile infection​
  • Cidrap EDU, Clostridium difficile, RSS
Fidaxomicin underused for C diff infections, study finds​
  • Cidrap EDU, Clostridium difficile, RSS
VA trial finds no reduction in C diff recurrence after fecal microbiota therapy​
  • Cidrap EDU, Clostridium difficile, RSS
Narrow-spectrum drug shows promise against C diff infection in phase 2 trial​
  • Cidrap EDU, Clostridium difficile, RSS
C difficile vaccine candidate fails to meet primary end point in phase 3 trial​
  • Cidrap EDU, Clostridium difficile, RSS
Study reveals how microbiota-based treatment may help prevent recurrent C diff​
  • Cidrap EDU, Clostridium difficile, RSS
Specialist-led intervention program linked to better management of C diff patients​
Load More
  • Cidrap EDU, Clostridium difficile, RSS
Study highlights optimal strategies for fecal transplantation in C diff patients​
  • Cidrap EDU, Clostridium difficile, RSS
Trial data show Rebyota is safe, effective in immune-compromised patients with recurrent C diff​
  • Cidrap EDU, Clostridium difficile, RSS
Study examines C diff recurrence, risk factors in cancer patients​
  • Cidrap EDU, Clostridium difficile, RSS
Study highlights demographic, socioeconomic disparities in C difficile infection​
  • Cidrap EDU, Clostridium difficile, RSS
Fidaxomicin underused for C diff infections, study finds​
  • Cidrap EDU, Clostridium difficile, RSS
VA trial finds no reduction in C diff recurrence after fecal microbiota therapy​
  • Cidrap EDU, Clostridium difficile, RSS
Narrow-spectrum drug shows promise against C diff infection in phase 2 trial​
  • Cidrap EDU, Clostridium difficile, RSS
C difficile vaccine candidate fails to meet primary end point in phase 3 trial​
  • Cidrap EDU, Clostridium difficile, RSS
Study reveals how microbiota-based treatment may help prevent recurrent C diff​
  • Cidrap EDU, Clostridium difficile, RSS
Specialist-led intervention program linked to better management of C diff patients​

One Health,
One Society:
Bridging Disciplines
for a Healthier World

MENU

NEWSLETTER

Subscribe to our newsletter and stay up to date with all events coming straight in your mailbox:

FOLLOW US

Facebook X-twitter Instagram Linkedin
Copyright © 2025 BioUnison LLC, All Rights Reserved.
One Health Society: A BioUnison Initiative
Privacy Policy | Terms of use